Point72 Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.23M | Buy |
+8,808
| New | +$1.23M | ﹤0.01% | 2621 |
|
|
2025
Q3 | – | Sell |
-164,728
| Closed | -$18.3M | – | 2455 |
|
|
2025
Q2 | $18.3M | Sell |
164,728
-346,008
| -68% | -$36.8M | 0.04% | 535 |
|
|
2025
Q1 | $57.2M | Sell |
510,736
-345,921
| -40% | -$35.7M | 0.13% | 191 |
|
|
2024
Q4 | $79.1M | Sell |
856,657
-1,448,613
| -63% | -$130M | 0.17% | 133 |
|
|
2024
Q3 | $193M | Buy |
2,305,270
+1,793,145
| +350% | +$137M | 0.49% | 15 |
|
|
2024
Q2 | $35.1M | Buy |
512,125
+154,525
| +43% | +$10.3M | 0.09% | 283 |
|
|
2024
Q1 | $26.2M | Buy |
+357,600
| New | +$27.5M | 0.06% | 365 |
|
|
2023
Q4 | – | Sell |
-602
| Closed | -$45.1K | – | 2388 |
|
|
2023
Q3 | $45.1K | Buy |
+602
| New | +$46.3K | ﹤0.01% | 2156 |
|
|
2023
Q2 | – | Sell |
-46,585
| Closed | -$3.87M | – | 2397 |
|
|
2023
Q1 | $3.87M | Buy |
+46,585
| New | +$3.86M | 0.01% | 833 |
|
|
2022
Q4 | – | Sell |
-562,900
| Closed | -$34.7M | – | 1615 |
|
|
2022
Q3 | $34.7M | Buy |
+562,900
| New | +$35.5M | 0.14% | 194 |
|
|
2022
Q2 | – | Sell |
-125,000
| Closed | -$7.43M | – | 1475 |
|
|
2022
Q1 | $7.43M | Buy |
+125,000
| New | +$7.99M | 0.03% | 593 |
|
|
2021
Q2 | – | Sell |
-1,813,444
| Closed | -$117M | – | 1045 |
|
|
2021
Q1 | $117M | Buy |
1,813,444
+1,201,301
| +196% | +$77.5M | 0.55% | 30 |
|
|
2020
Q4 | $35.7M | Buy |
+612,143
| New | +$36.9M | 0.17% | 155 |
|
|
2020
Q1 | – | Sell |
-402,631
| Closed | -$26.2M | – | 890 |
|
|
2019
Q4 | $26.2M | Buy |
+402,631
| New | +$26.2M | 0.14% | 210 |
|
|
2019
Q3 | – | Sell |
-10,100
| Closed | -$682K | – | 1241 |
|
|
2019
Q2 | $682K | Buy |
+10,100
| New | +$664K | ﹤0.01% | 807 |
|
|
2019
Q1 | – | Sell |
-548,917
| Closed | -$34.3M | – | 1095 |
|
|
2018
Q4 | $34.3M | Sell |
548,917
-698,365
| -56% | -$48.8M | 0.17% | 162 |
|
|
2018
Q3 | $96.3M | Sell |
1,247,282
-1,923,449
| -61% | -$145M | 0.4% | 65 |
|
|
2018
Q2 | $225M | Buy |
3,170,731
+92,165
| +3% | +$6.51M | 0.9% | 14 |
|
|
2018
Q1 | $232M | Buy |
3,078,566
+2,836,662
| +1,173% | +$225M | 0.97% | 11 |
|
|
2017
Q4 | $17.3M | Buy |
+241,904
| New | +$18.4M | 0.07% | 330 |
|
|
2017
Q3 | – | Sell |
-1,272,910
| Closed | -$90.1M | – | 936 |
|
|
2017
Q2 | $90.1M | Buy |
1,272,910
+706,810
| +125% | +$47M | 0.51% | 35 |
|
|
2017
Q1 | $38.5M | Buy |
+566,100
| New | +$39.8M | 0.21% | 129 |
|
|
2016
Q4 | – | Sell |
-141,000
| Closed | -$11.2M | – | 752 |
|
|
2016
Q3 | $11.2M | Sell |
141,000
-518,100
| -79% | -$42.1M | 0.08% | 264 |
|
|
2016
Q2 | $55M | Buy |
659,100
+658,400
| +94,057% | +$58.4M | 0.37% | 55 |
|
|
2016
Q1 | $64K | Buy |
+700
| New | +$63.1K | ﹤0.01% | 698 |
|
|
2015
Q2 | – | Sell |
-1,158,000
| Closed | -$114M | – | 762 |
|
|
2015
Q1 | $114M | Buy |
1,158,000
+96,900
| +9% | +$9.84M | 0.77% | 19 |
|
|
2014
Q4 | $100M | Buy |
+1,061,100
| New | +$110M | 0.7% | 15 |
|
Other funds holding GILD
VCM
VPM
Point72 Asset Management's GILD Position: Q1 2026 in Review
Point72 Asset Management opened a new position in Gilead Sciences (GILD) in Q1 2026: 8,808 shares worth $1.23M. The stake represents ﹤0.01% of the portfolio and ranks #2621 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in GILD as recently as Q2 2025.
Point72 Asset Management first reported a position in GILD in Q4 2014 and has held it in 27 quarters since. The position peaked at $232M in Q1 2018. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Point72 Asset Management held 8,808 shares of Gilead Sciences worth $1.23M as of Q1 2026.
- Gilead Sciences was a new Point72 Asset Management position in Q1 2026.
- Gilead Sciences made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2621 holding.
- Point72 Asset Management first reported a position in Gilead Sciences in Q4 2014 and has held it in 27 quarters since.
- Point72 Asset Management's Gilead Sciences position peaked at $232M in Q1 2018.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.